Breakthrough Findings in Parkinson's Treatment
Stockholm - Karolinska Development AB (NASDAQ: KDEV) is thrilled to share the latest exciting research from its portfolio company, Umecrine Cognition. They have recently published compelling data in the scientific journal Neuropharmacology, emphasizing the significant benefits of initiating treatment with golexanolone early in the progression of Parkinson's disease. This breakthrough suggests that early intervention may not only delay the worsening of symptoms but could also reduce the necessity for L-DOPA therapy in patients diagnosed with this debilitating condition.
Understanding Parkinson’s Disease
Parkinson’s disease, a complex neurodegenerative disorder, is primarily characterized by a progressive decline in motor functions, cognitive abilities, and mental health. This condition arises from the progressive loss of dopamine-producing neurons in the brain, which leads to a multitude of symptoms that profoundly impact quality of life. Umecrine Cognition's goal is to advance a novel class of treatments specifically designed to address these cognitive impairments.
The Efficacy of Golexanolone
A recent preclinical study sheds light on the benefits of golexanolone when administered shortly after the onset of Parkinson's symptoms. The findings showed that early administration resulted in significantly better symptom relief than when treatment began at a later stage. Remarkably, patients showed notable reductions in symptoms such as fatigue and reduced movement. Additionally, there were marked improvements in motor coordination and overall motor function.
These results suggest that golexanolone could play a vital role in correcting imbalances in neurotransmitter systems critical to Parkinson’s pathology, positioning it as a potential treatment that modifies the disease rather than merely alleviating symptoms.
Publication and Research Ownership
The noteworthy results from Umecrine Cognition's study were featured in the latest edition of Neuropharmacology. Karolinska Development proudly notes that it maintains a 60% ownership stake in Umecrine Cognition, which underscores their commitment to supporting innovative therapeutic solutions.
Contact Information
For more insights or inquiries regarding this groundbreaking research, please reach out to:
Viktor Drvota, CEO
Karolinska Development AB
Phone: +46 73 982 52 02
Email: viktor.drvota@karolinskadevelopment.com
Johan Dighed, General Counsel and Deputy CEO
Karolinska Development AB
Phone: +46 70 207 48 26
Email: johan.dighed@karolinskadevelopment.com
About Karolinska Development AB
Karolinska Development AB is a leading Nordic investment company focused on the life sciences. The firm specializes in identifying and nurturing groundbreaking medical innovations arising within the Nordic region, providing essential support to entrepreneurs and their teams. Their mission revolves around transforming promising scientific assets into viable commercial products that aim to enhance patient well-being while delivering favorable returns on investment.
The company’s access to premier medical innovations, especially those associated with the Karolinska Institutet and other prominent research institutions, positions them as leaders in the field. Karolinska Development is devoted to fostering companies led by accomplished scientists, supported by expert management and advisors, to ensure optimal development and success.
Karolinska Development proudly manages a diverse portfolio of eleven companies, all dedicated to addressing critical opportunities in the innovation of treatments for severe and life-threatening diseases. The team comprises seasoned investment professionals renowned for their ability to build successful companies and maintain extensive global connections.
Frequently Asked Questions
What is the main focus of Umecrine Cognition's research?
Umecrine Cognition focuses on developing treatments that address cognitive symptoms in Parkinson’s disease.
How does golexanolone work in the treatment of Parkinson's disease?
Golexanolone may help rebalance neurotransmitter systems in the brain, potentially modifying the disease rather than providing only symptomatic relief.
What are the significant findings from the research published in Neuropharmacology?
The research indicates that early treatment with golexanolone leads to greater and longer-lasting relief from Parkinson’s symptoms.
How much of Umecrine Cognition does Karolinska Development own?
Karolinska Development owns a 60% stake in Umecrine Cognition.
Who can I contact for more information about this research?
Viktor Drvota and Johan Dighed from Karolinska Development can be contacted for further inquiries.
